Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)

Alvaro Moreno-Aspitia,Eileen M. Holmes,Christian Jackisch,Evandro de Azambuja,Frances Boyle,David W. Hillman, Larissa Korde,Debora Fumagalli,Miguel A. Izquierdo,Ann E. McCullough,Antonio C. Wolff,Kathleen I. Pritchard,Michael Untch, Sébastien Guillaume,Michael S. Ewer,Zhimin Shao,Sung Hoon Sim,Zeba Aziz,Georgia Demetriou,Ajay O. Mehta

European Journal of Cancer（2021）

引用 15|浏览7

暂无评分

摘要

•First phase III study of adjuvant dual HER2 blockade for HER2+ breast cancer.•8381 patients with stage I-III HER2+ breast cancer, followed for at least 5 years.•Compared chemotherapy + trastuzumab versus chemotherapy + 3 lapatinib-containing arms.•Lapatinib associated with increased non-cardiac.•Chemotherapy + lapatinib/trastuzumab not superior to chemotherapy + trastuzumab.

查看译文

关键词

Early breast cancer,HER2,Lapatinib,Trastuzumab,Adjuvant chemotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要